Press Release

Thalassemia Treatment Market to be Dominated by Asia Pacific through 2028

Increasing research & development to identify potential treatment regime for thalassemia is expected to drive the growth of global thalassemia treatment market in the forecast period, 2024-2028.


According to TechSci Research report, “Thalassemia Treatment Market –Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”, global thalassemia treatment market is expected to grow during the forecast period of 2024-2028. This can be ascribed to the increasing incidences of thalassemia, advancement in technologies, and growing healthcare expenditure.

Several factors are driving global thalassemia treatment market, including strategic partnership and collaboration, the growing burden of thalassemia in endemic regions, and the rising healthcare spending for availability of effective thalassemic prevention resources. The development of different therapies for the treatment of thalassemia and understanding the complex nature of thalassemia are driving the growth of the market. Finally, the increasing awareness of the importance of early diagnosis and the potential benefits of a thalassemia medication are contributing to the growth of the global thalassemia treatment market. These factors are expected to continue to drive the growth of the global thalassemia treatment market in the coming years.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Thalassemia Treatment Market"


Global Thalassemia Treatment Market can be segmented by type and region.

Based on type, global thalassemia treatment market can be divided into blood transfusions, iron chelation therapy (exjade/jadenu (deferasirox), ferriprox (deferiprone), desferal (deferoxamine), blood & bone marrow transplant, and others. The blood transfusion and iron chelation segment is expected to dominate the global thalassemia treatment market in the coming years due to the effectiveness of blood transfusions are a common treatment for thalassemia major, as they help to maintain hemoglobin levels and prevent complications associated with anemia. Iron chelation therapy is used to manage iron overload, which is a common complication of thalassemia that can lead to organ damage. Commonly used iron chelators include deferoxamine (Desferal), deferiprone (Ferriprox), and deferasirox (Exjade/Jadenu) therefore the blood transfusion and iron chelation segment is expected to continue dominating the global thalassemia treatment market in the coming years.

Global thalassemia treatment market is divided into North America, Europe, Asia Pacific, South America and Middle East & Africa, based on region. The Asia pacific region is expected to dominate the global thalassemia treatment market in the coming years due to the high prevalence of thalassemia in the region. Asia Pacific is considered a major market for thalassemia treatment due to the high prevalence of thalassemia in the region. For example, thalassemia is particularly common in Southeast Asia, where it is estimated that up to 5% of the population may be carriers of the disease. As a result, there is a significant demand for thalassemia treatments in the region are expected to drive the growth of the market. Therefore, the Asia Pacific region is likely to dominate the global thalassemia treatment market in the coming years.


Major companies operating in global thalassemia treatment market are:

  • Bluebird bio, Inc
  • Acceleron Pharma, Inc
  • Celgene Corporation
  • GlaxoSmithKline plc
  • Incyte Corporation
  • La Jolla Pharmaceuticals, Inc
  • Sanofi S.A.
  • Lonza Group Ltd.
  • ApoPharma Inc


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“Global thalassemia treatment market is rapidly evolving, with significant advancements in vaccine technology and an increasing number of pharmaceutical companies for medication. The market is dominated by blood transfusion, which are often used to treat the anemia that results from a lack of healthy red blood cells. There is a growing focus on early diagnosis, patient education, research funding, and public policy. Technological advancements, such as the use of gene therapy and stem cell transplantation, are driving the development of more effective medications. Additionally, there is a growing emphasis on the need for medications that are effective against all thalassemic genetic disorders, including beta thalassemia. The increasing number of clinical trials and partnerships between public and private sectors bodes well for the future of the thalassemia treatment market, with several promising medications candidates currently in advanced stages of development.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Thalassemia Treatment Market- Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented By Type (Blood Transfusions, Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), and Desferal (deferoxamine)), Blood & Bone Marrow Transplant, and Others), By Region and Competition,” has evaluated the future growth potential of global thalassemia treatment market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global thalassemia treatment market.

 

Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email:
 [email protected]
Website: 
https://www.techsciresearch.com